

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Christophe Beraud et al.

Application No.: To Be Assigned

Filed: Herewith

For: NOVEL MOTOR PROTEINS AND
METHODS FOR THEIR USE

Customer No.: 20350

Examiner: Unassigned

Art Unit: Unassigned

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:


The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. In accordance with 37 CFR §1.98(d), copies of the references can be found in Application No. 09/594,655, filed June 15, 2000 (Attorney Docket No. 20552-001400US), with the exception of reference numbers AI, AR, AU-AV, and AY, which can be found in Application No. 09/883,096, filed June 15, 2001. Also a copy of the Search/Examination report corresponding to the PCT application can be found in Application No. 09/883,096, filed June 15, 2001. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference

should be made that the information and references cited are prior art merely because they are in this statement.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Scott L. Ausenhus
Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 303-571-4000
Fax: 415-576-0300
SLA:bhr

60087985 v1

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	Not Yet Assigned
				Filing Date	Herewith
				First Named Inventor	Beraud, Christophe
				Group Art Unit	
				Examiner Name	Unassigned
Sheet	1	of	3	Attorney Docket Number	020552-001411US

U.S. PATENT DOCUMENTS						
Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS								
Examiner Initials*	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)				

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60087985 v1

Please type a plus sign (+) inside this box → +

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>			Complete if Known	
			Application Number	Not Yet Assigned
			Filing Date	Herewith
			First Named Inventor	Beraud, Christophe
			Group Art Unit	
			Examiner Name	Unassigned
Sheet 2	of	3	Attorney Docket Number	020552-001411US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	AA	AHN et al., "The Structural and functional diversity of dystrophin," <u>Nature Genetics</u> , 3:283-291 (1993).		
	AB	BURGESS et al., "Possible Dissociation of the Heparin-binding and Mitogenic Activities of Heparin0binding (Acidic Fibroblast) Growth Factor-1 from Its Receptor-binding Activities by Site-directed Mutagenesis of a Single Lysine Residue," <u>J. Cell Biol.</u> , 111:2129-2138 (1990).		
	AC	BORK, P., "Powers and pitfalls in sequence analysis: the 70% hurdle," <u>Genome Research</u> , 10:398-400 (2000)		
	AD	BOWIE et al., "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions," <u>Science</u> , 247:1306-1310 (1990).		
	AE	CAWTHON et al., "cDNA Sequence and Genomic Structure of <i>EV12B</i> , a Gene Lying within an Intron of the Neurofibromatosis Type 1 Gene," <u>Genomics</u> , 9:446-460 (1991).		
	AF	DEBERNARDI et al., "Identification of a Novel Human Kinesin-Related Gene (HK2) by the cDNA Differential Display Technique," <u>Genomics</u> , 42:67-73 (1997).		
	AG	DE PLAEN et al., "Structure, chromosomal localization, and expression of 12 genes of the MAGE family," <u>Immunogenetics</u> , 40:360-369 (1994).		
	AH	EFFERTH et al., "Involvement of the kinesin heavy chain in the sequence dependent synergism of taxol and cisplatin," <u>Proceedings of the American Association for Cancer Research</u> , 37:378, abstract # 2579 (1996).		
	AI	GURA, T., "Systems for Identifying New Drugs Are Often Faulty," <u>Science</u> , 278:1041-1042 (1997).		
	AJ	HARRIS et al., "Polycystic Kidney Disease 1: Identification and Analysis of the Primary Defect," <u>J. of American Society of Nephrology</u> , 6:1125-1133 (1995).		
	AK	HIROKAWA et al., "Kinesin and Dynein Superfamily Proteins and the Mechanism of Organelle Transport," <u>Science</u> , 279:519-526 (1998).		
	AL	LAZAR et al., "Transforming Growth Factor α : Mutation of Aspartic Acid 47 and Leucine 48 Results in Different Biological Activities," <u>Mol. and Cellular Biol.</u> , 8(3):1247-1252 (1988).		
	AM	NAGAI et al., "Identification of the full-length <i>KIAA0591</i> gene encoding a novel kinesin-related protein which is mapped to the neuroblastoma suppressor gene locus at 1p36.2," <u>Int. J. Oncology</u> , 16:907-916 (2000).		
	AN	PEREIRA et al., "Mitochondrial association of a plus end-directed microtubule motor expressed during mitosis in <i>Drosophila</i> ," <u>J. Cell Biol.</u> , 136:1081-1090 (2000).		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60087985 v1

Please type a plus sign (+) inside this box →



PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet **3** of **3**

Complete if Known

Application Number	Not Yet Assigned
Filing Date	Herewith
First Named Inventor	Beraud, Christophe
Group Art Unit	
Examiner Name	Unassigned
Attorney Docket Number	020552-001411US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AO	PURNELLE et al., Genbank Accession # AL023587. Direct Submission, S. pombe chromosome II cosmid c649 (1988).	
	AP	REIGER et al., <i>Glossary of Genetics and Cytogenetics: Classical and Molecular, 4th edition</i> , Springer-Verlag, Berlin, pages 17-18 (1976).	
	AQ	RIEGER et al., Genbank Accession #Z72739; Y3135. Direct Submission, S. cerevisiae chromosome VII (1996).	
	AR	SAKOWICZ et al., "A Marine Natural Product Inhibitor of Kinesin Motors," <i>Science</i> , 280:292-295 (1998).	
	AS	SIPPEL et al., "Site-directed Mutagenesis within an Ectoplasmic ATPase Consensus Sequence Abrogates the Cell Aggregating Properties of the Rat Liver Canalicular Bile Acid Transporter/Ecto-ATPase/Cell CAM 105 and Carcinoembryonic Antigen*,-," <i>J. Biol. Chem.</i> , 27(51):33095-33104 (1996).	
	AT	STEWART et al., Genbank Accession #U89264. Direct submission, Dm Kinesin-like protein 67a (1997).	
	AU	SUGANO et al., GenBank Accession #AW154058, "cloned polynucleotide sequence encodes a kinesin that has an amino acid sequence that is 100% identical to SEQ ID BO: 2," (1999)	
	AV	TUCKER et al., "Probing the Kinesin-Microtubule Interaction*," <i>J. Biol. Chem.</i> , 272(14):9481-9488 (1997).	
	AW	WOEHLKE et al., "Microtubule Interaction Site of the Kinesin Motor," <i>Cell</i> , 90:207-216 (1997).	
	AX	WOOD et al., Genbank Accession #Z97211. Direct Submission. S. pombe chromosome II cosmid c2F12 (1997).	
	AY	Genbank Accession #BG420786, NIH-MGC http://mgc.nci.nih.gov/ . "polynucleotide sequence comprises a sequence that is greater than 60% identical to SEQ ID NO: 1 (1999).	

Examiner
Signature

Date
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
60087985 v1